GSK3b (C199A)
Sign in to save this workspaceGSK3B · Variant type: point · HGVS: p.C199A
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Abemaciclib | 70.1% | 29.9% | 91.48 |
| 2 | Darovasertib | 11.0% | 89.0% | 96.99 |
| 3 | Sunitinib | 8.9% | 91.1% | 91.73 |
| 4 | Vandetanib | 8.5% | 91.5% | 95.74 |
| 5 | Gilteritinib | 5.3% | 94.7% | 88.97 |
| 6 | Palbociclib | 5.2% | 94.8% | 98.75 |
| 7 | Repotrectinib | 4.5% | 95.5% | 84.21 |
| 8 | Erlotinib | 4.4% | 95.6% | 99.75 |
| 9 | Cobimetinib | 4.3% | 95.7% | 100.00 |
| 10 | Acalabrutinib | 3.2% | 96.8% | 99.50 |
| 11 | Quizartinib | 1.4% | 98.6% | 99.50 |
| 12 | Canertinib | 0.0% | 100.0% | 96.49 |
| 13 | Capivasertib | 0.0% | 100.0% | 96.48 |
| 14 | Remibrutinib | 0.0% | 100.0% | 99.50 |
| 15 | Inavolisib | 0.0% | 100.0% | 100.00 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Abemaciclib | 70.1% | 96.5% | -26.3% |
| Darovasertib | 11.0% | 36.8% | -25.7% |
| Sunitinib | 8.9% | — | — |
| Vandetanib | 8.5% | — | — |
| Gilteritinib | 5.3% | — | — |
| Palbociclib | 5.2% | — | — |
| Repotrectinib | 4.5% | — | — |
| Erlotinib | 4.4% | — | — |
| Cobimetinib | 4.3% | — | — |
| Acalabrutinib | 3.2% | — | — |
| Quizartinib | 1.4% | — | — |
| Canertinib | 0.0% | 16.1% | -16.1% |
| Capivasertib | 0.0% | — | — |
| Remibrutinib | 0.0% | — | — |
| Inavolisib | 0.0% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| carcinoma_breast | Breast | ref |
| carcinoma_pancreas | Pancreas | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 11.7ms